Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Autolus Therapeutics Plc (AUTL), Anchiano Therapeutics Ltd (ANCN) and Eloxx Pharmaceuticals Inc (ELOX).
Autolus Therapeutics Plc (AUTL)
In a report released today, Debjit Chattopadhyay from H.C. Wainwright maintained a Buy rating on Autolus Therapeutics Plc, with a price target of $45. The company’s shares closed on Friday at $27.06.
Chattopadhyay commented:
“We envision upside to our target if the upcoming data reflect the anticipated advantages of Autolus’ CAR T assets. Our $45 price target is derived from a risk-adjusted, sum-of-the-parts analysis that drives our DCF model. Our DCF is based on: beta of 1.46, terminal growth rate of 0.5%, risk premium of 4.93%, calculated WACC of 10.0%, and tax rate of 15% beginning in FY 2027.”
According to TipRanks.com, Chattopadhyay is a 3-star analyst with an average return of 0.7% and a 45.0% success rate. Chattopadhyay covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Mersana Therapeutics Inc, and Voyager Therapeutics Inc.
Autolus Therapeutics Plc has an analyst consensus of Moderate Buy, with a price target consensus of $45.
See today’s analyst top recommended stocks >>
Anchiano Therapeutics Ltd (ANCN)
Anchiano Therapeutics Ltd received a Buy rating and a $16 price target from Oppenheimer analyst Leland Gershell today. The company’s shares closed on Friday at $7.72, close to its 52-week low of $7.33.
Gershell said:
“We are initiating coverage of ANCN with an Outperform rating and a $16 price target. ANCN is committed to expanding treatment options for non-muscle invasive bladder cancer (NMIBC) through its development of inodiftagene, a targeted biotherapeutic. An ongoing trial in the treatment-refractory setting could provide a short path to a ~$250M sales opportunity in the US alone, and relevant clinical data coupled with a modest regulatory bar fuels our optimism for success. Plans to evaluate inodiftagene in earlier-line therapy could meaningfully expand its commercial potential. We believe upcoming interim reveals from the potential registration trial will capture investors’ attention through 2019.”
According to TipRanks.com, Gershell is a 1-star analyst with an average return of -3.9% and a 30.2% success rate. Gershell covers the Healthcare sector, focusing on stocks such as Evofem Biosciences Inc, AzurRx BioPharma Inc, and Urogen Pharma Ltd.
The word on The Street in general, suggests a Hold analyst consensus rating for Anchiano Therapeutics Ltd.
Eloxx Pharmaceuticals Inc (ELOX)
In a report released today, Andrew Fein from H.C. Wainwright reiterated a Hold rating on Eloxx Pharmaceuticals Inc, with a price target of $10. The company’s shares closed on Friday at $11.76.
Fein wrote:
“Our price target of $10/share is based on an equally-weighted composite of: (a) $9.01/share, as a 35x multiple of taxed and diluted $2.75 discounted back to FY19 at 20% (in line with the expected P/E multiple and discount rate of an early development-stage biotechnology company); and (b) an NPV of $10.75/ share (discounted cash flow analysis using a 12% discount rate and 3.5% growth rate, in line with the expected discount and growth parameters of an early development-stage biotechnology company).”
According to TipRanks.com, Fein is a 5-star analyst with an average return of 8.6% and a 45.8% success rate. Fein covers the Healthcare sector, focusing on stocks such as Constellation Pharmaceuticals Inc, DBV Technologies SA – American, and Proteostasis Therapeutics Inc.
The word on The Street in general, suggests a Hold analyst consensus rating for Eloxx Pharmaceuticals Inc with a $10 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
